4.00
+0.13(+3.36%)
Currency In USD
| Previous Close | 3.87 |
| Open | 3.81 |
| Day High | 4.04 |
| Day Low | 3.76 |
| 52-Week High | 11.88 |
| 52-Week Low | 3.61 |
| Volume | 710,692 |
| Average Volume | 1.24M |
| Market Cap | 282.36M |
| PE | -2.34 |
| EPS | -1.71 |
| Moving Average 50 Days | 4.99 |
| Moving Average 200 Days | 5.9 |
| Change | 0.13 |
If you invested $1000 in C4 Therapeutics, Inc. (CCCC) since IPO date, it would be worth $156.14 as of December 26, 2024 at a share price of $3.98. Whereas If you bought $1000 worth of C4 Therapeutics, Inc. (CCCC) shares 3 years ago, it would be worth $120.72 as of December 26, 2024 at a share price of $3.98.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader
GlobeNewswire Inc.
Dec 08, 2024 5:30 PM GMT
In Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest Dose Level Explored to Date Achieved 36 Percent Overall Response Rate (ORR) and 45 Percent Clinical Benefit Rate (CBR); Responses Seen Across All Dose Levels Multiple Myelo
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors
GlobeNewswire Inc.
Nov 20, 2024 12:00 PM GMT
Hoerter Brings Over Three Decades of Oncology Commercialization and Leadership Experience Appointment Underscores Continued Transformation of Board to Lead C4T into Next Phase of Pipeline Progress WATERTOWN, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) --
C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial
GlobeNewswire Inc.
Nov 06, 2024 12:00 PM GMT
Clinical Development Initiated in Greater China by Partner Betta PharmaceuticalsWATERTOWN, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing target